Nintedanib With or Without Dextromethorphan in Patients With Idiopathic Pulmonary Fibrosis (IPF)
A Multicenter, Randomized, Double Blind, Placebo-controlled Clinical Study to Evaluate the Treatment of Nidanib With or Without Dextromethorphan in Idiopathic Pulmonary Fibrosis (IPF) Patients.
Aperçu de l'étude
Statut
Statut
Les conditions
Les conditions
Intervention / Traitement
Intervention / Traitement
Type d'étude
Type d'étude
Inscription (Estimé)
Inscription
Phase
Phase
- Phase 2
Critères de participation
Critère d'éligibilité
Critère d'éligibilité
Âges éligibles pour étudier
- Adulte
- Adulte plus âgé
Accepte les volontaires sains
La description
Inclusion Criteria:
- Age ≥40 years old, regardless of gender;
- According to "2022 ATS/ERS/JRS/ALAT Guidelines", it was diagnosed as idiopathic pulmonary fibrosis (IPF);
- Lung function meets the following conditions during screening: forced vital capacity (FVC) ≥45% predicted value; The dispersion of carbon monoxide (DLco, corrected Hb) in a single breath is between 30% and 80% of the predicted value.
- HRCT images completed within 12 months before screening can be used to determine UIP mode;
- It is expected to complete the whole research plan, including 12 weeks of treatment and 1 week of follow-up;
- Willing to follow all the requirements of drug use, visit and data collection during the study period;
- Be able to understand the research content and sign the written informed consent;
- Women of childbearing age provide negative pregnancy test results, and agree to take effective contraceptive measures during the study period and within 3 months after the last administration; Male subjects with fertility also need to take effective contraception at the same time.
Exclusion Criteria:
- Suffering from other interstitial lung diseases caused by non-IPF reasons (such as connective tissue disease-related ILD, chronic allergic pneumonia, pneumoconiosis, drug-induced pneumonia, radiation lung disease, etc.);
- One or more Acute Exacerbation); of IPF occurred within 3 months before screening;
- Have received a lung transplant;
- Complicated with severe COPD(GOLD III and above), severe asthma or other airway diseases that may interfere with FVC determination;
- The following systemic immunosuppressive treatments were used within 4 weeks before screening: > 15 mg/d prednisone (or equivalent dose), cyclophosphamide, methotrexate, tuzumab, rituximab, mycophenolate mofetil, etc.
- Currently or in the past, allergic to Nidanib, dextromethorphan or any of its auxiliary ingredients;
- The following laboratory abnormalities exist: ALT or AST >3×ULN;; eGFR <30 mL/min/1.73m²;
- Have a history of uncontrolled mental illness, epilepsy, central nervous system dysfunction, or may induce adverse reactions after using dextromethorphan;
- Being receiving drugs that may have serious drug interaction with dextromethorphan, such as monoamine oxidase inhibitor (MAOI) and selective serotonin reuptake inhibitor (SSRI), and unable to stop taking drugs;
- Pregnant or lactating women;
- At the time of screening, there are other major diseases or medical conditions that researchers think will significantly increase the risk and affect the treatment compliance or data interpretation;
- Interventional treatment of other clinical trials within 4 weeks before screening.
- Use Nidanib or pirfenidone for anti-fibrosis treatment within 8 weeks before screening;
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Quadruple
Nombre de bras
Armes et Interventions
Groupe de participants / BrasGroupe de participants / Bras |
Intervention / TraitementIntervention / Traitement |
|---|---|
|
Expérimental: Experimental group
Experimental: The dosage of Nintedanib is 150mg/100mg per dose, twice daily;The dosage of Dextromethorphan is 30mg per dose, twice daily.
|
Dosage of Nitedanib is 150mg/100mg each time, twice a day, once in the morning and once in the evening, It is recommended to take it with meals.
The dosage of Dextromethorphan sustained-release tablets is 30 mg, twice a day.
It is recommended to take it orally 30 minutes after meals.
For 12 weeks.
|
|
Comparateur placebo: Control group
Control group:The dosage of Nintedanib is 150mg/100mg per dose, twice daily;Placebo take orally twice daily.
|
Dosage of Nitedanib is 150mg/100mg each time, twice a day, once in the morning and once in the evening, with an interval of 12hours.
It is recommended to take it with meals to reduce gastrointestinal adverse reactions.
Placebo, twice a day, recommended to be taken in the morning and evening.
For 12 weeks.
|
Que mesure l'étude ?
Principaux critères de jugement
Principaux critères de jugement
Mesure des résultats |
Délai |
|---|---|
|
FVC
Délai: The change in FVC from baseline at week 12 after administration
|
The change in FVC from baseline at week 12 after administration
|
Mesures de résultats secondaires
Mesures de résultats secondaires
Mesure des résultats |
Délai |
|---|---|
|
Leicester Cough score (LCQ)
Délai: Change in score from baseline to week 12
|
Change in score from baseline to week 12
|
|
Symptoms and Effects Scale(L-PF)
Délai: Change in score from baseline to week 12
|
Change in score from baseline to week 12
|
|
Incidence Rate of Acute Aggravating Events(%predicted)
Délai: Incidence Rate of Acute Aggravating Events during the 12-week study period
|
Incidence Rate of Acute Aggravating Events during the 12-week study period
|
|
DLCO(%predictedl)
Délai: Change in score from baseline to week 12
|
Change in score from baseline to week 12
|
|
Incidence of Treatment-related adverse Events
Délai: The assessments need to be conducted four times at baseline and at weeks and 12 after medication
|
The assessments need to be conducted four times at baseline and at weeks and 12 after medication
|
Collaborateurs et enquêteurs
Parrainer
Parrainer
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Estimé)
Début de l'étude
Achèvement primaire (Estimé)
Achèvement primaire
Achèvement de l'étude (Estimé)
Achèvement de l'étude
Dates d'inscription aux études
Première soumission
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Première publication
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour publiée
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
- Maladies des voies respiratoires
- Maladies pulmonaires
- Maladies pulmonaires interstitielles
- Fibrose pulmonaire
- Fibrose pulmonaire idiopatique
- Composés hétérocycliques
- Composés hétérocycliques, anneau fusionné
- Alcaloïdes
- Hydrocarbures aromatiques polycycliques
- Composés polycycliques
- Composés hétérocycliques, 4 anneaux ou plus
- Morphinans
- Alcaloïdes opiacés
- Composés hétérocycliques, anneau ponté
- Phénanthrène
- Dextrométhorphane
- nintedanib
Autres numéros d'identification d'étude
Autres numéros d'identification d'étude
- Dextro-Nin-IPF-II
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
produit fabriqué et exporté des États-Unis.
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .